Theriva Biologics, Inc. — 10-Q summary
Filing identity: The supplied filing is for Synthetic Biologics, Inc. (Nevada), not Theriva Biologics, Inc. It covers the quarter and six months ended June 30, 2016; the financial statements are unaudited. The company describes itself as a clinical-stage therapeutics developer.
Business context and pipeline
Lead Phase 2 programs were SYN-010 for IBS-C and SYN-004 (ribaxamase) to protect the gut microbiome during IV beta-lactam antibiotic treatment. Other programs included preclinical SYN-005 for pertussis, discovery-stage programs for PKU and intestinal alkaline phosphatase, and preclinical SYN-007. The company discontinued its multiple sclerosis program in February 2016.
Financial performance and position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | No material revenue reported; filing says revenue was minimal and none expected near term | No material revenue reported; filing says revenue was minimal and none expected near term |
| Operating costs and expenses | $9.3 million, versus $9.7 million in 2015 | $19.9 million, versus $17.9 million in 2015 |
| Operating loss | $9.3 million, versus $9.7 million | $19.9 million, versus $17.9 million |
| Net loss | $5.8 million, versus $13.6 million | $16.8 million, versus $26.0 million |
| Net loss per basic share | $0.06, versus $0.19 | $0.18, versus $0.36 |
| Net cash used in operations | $11.5 million for the first half, versus $12.7 million in 2015 |
At June 30, 2016, cash and cash equivalents were $10.0 million, down from $20.8 million at December 31, 2015. Current assets were $15.8 million and current liabilities $15.2 million. Total liabilities were $15.4 million, including $7.6 million of warrant liabilities; the filing reports no borrowings. Stockholders’ equity was $0.9 million, compared with $15.0 million at year-end. No meaningful operating margin is applicable given the absence of material revenue.
Changes and unusual items
- First-half R&D expense rose 9% to $15.3 million, while G&A rose 16% to $4.6 million. For the quarter, R&D declined 5% and G&A declined 3% year over year.
- Net loss improved substantially versus 2015, mainly because the warrant-liability fair-value change contributed $3.0 million of noncash income in the first half of 2016, versus $8.0 million of noncash expense in 2015. This is not operating cash generation.
- First-half cash use from operations was partly offset by a $3.7 million reduction in prepaid expenses and other current assets. Financing cash flow was $0.8 million, mainly from stock-option exercises.
- Common shares outstanding were 91.27 million at June 30; 91.27 million were reported outstanding as of August 1, 2016.
Outlook, risks, and contingencies
- Management stated cash on hand was not expected to fund operations for the next 12 months. There were no committed financing sources; new capital may be unavailable or dilutive, and failure to obtain funding could force program delays, cuts, or discontinuation.
- Following a July 2016 FDA End-of-Phase-2 meeting, the company planned to submit a SYN-010 adaptive Phase 2b/3 protocol and statistical plan in the second half of 2016, with trial initiation targeted for Q1 2017.
- For ribaxamase, management anticipated an independent committee’s interim review of blinded Phase 2b data in the second half of 2016, topline results in Q1 2017, and Phase 3 trial initiation toward the end of 2017. These are forward-looking plans, not assured outcomes.
- The filing highlighted NYSE MKT continued-listing risk: stockholders’ equity was $0.931 million versus a cited $6.0 million minimum for companies with the specified loss history. Potential delisting could reduce liquidity and impair capital raising.
- Warrant fair value depends on Level 3 assumptions and may fluctuate. The company reported no material legal proceedings, no material changes in contractual obligations, and no off-balance-sheet arrangements.
Investor facts to verify
- Confirm the issuer: this source names Synthetic Biologics, Inc., although the request metadata names Theriva Biologics, Inc.
- Check subsequent financing, cash runway, and any changes to the company’s going-concern assessment or listing status.
- Track actual FDA interactions, trial starts, enrollment, interim reviews, and results against the stated SYN-010 and ribaxamase timelines.
- Separate operating performance from noncash warrant remeasurement when assessing the year-over-year net-loss improvement.
- Review dilution exposure from options and warrants, as well as any subsequent changes in shares outstanding.